# Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen

> **NCT04191343** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Biliary Tract Tumors

## Interventions

- **DRUG:** Toripalimab injection combined with GEMOX

## Key facts

- **NCT ID:** NCT04191343
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-14
- **Primary completion:** 2023-09
- **Final completion:** 2024-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04191343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04191343, "Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04191343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*